IL6 and COVID-19: In fact, although the data about MDRB colonization in COVID-19 are scant, the empirical treatment with broad spectrum antibiotic therapy and biologics that target and inhibit cytokines, such as IL-1 and IL-6, could raise the risk of MDRB colonization in these patients [25,26].